New Results
De novo design of ACE2 protein decoys to neutralize SARS-CoV-2
Thomas W. Linsky, Renan Vergara, Nuria Codina, Jorgen W. Nelson, Matthew J. Walker, Wen Su, Tien-Ying Hsiang, Katharina Esser-Nobis, Kevin Yu, Yixuan J. Hou, Tanu Priya, Masaya Mitsumoto, Avery Pong, Uland Y. Lau, Marsha L. Mason, Jerry Chen, Alex Chen, Tania Berrocal, Hong Peng, Nicole S. Clairmont, Javier Castellanos, Yu-Ru Lin, Anna Josephson-Day, Ralph Baric, Carl D. Walkey, Ryan Swanson, Michael Gale Jr, Luis M. Blancas-Mejia, Hui-Ling Yen, View ORCID ProfileDaniel-Adriano Silva
doi: https://doi.org/10.1101/2020.08.03.231340
Thomas W. Linsky
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Renan Vergara
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Nuria Codina
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Jorgen W. Nelson
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Matthew J. Walker
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Wen Su
2School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China
Tien-Ying Hsiang
3Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, WA 98195, USA
Katharina Esser-Nobis
3Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, WA 98195, USA
Kevin Yu
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Yixuan J. Hou
4Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Tanu Priya
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Masaya Mitsumoto
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Avery Pong
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Uland Y. Lau
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Marsha L. Mason
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Jerry Chen
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Alex Chen
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Tania Berrocal
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Hong Peng
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Nicole S. Clairmont
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Javier Castellanos
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Yu-Ru Lin
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Anna Josephson-Day
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Ralph Baric
4Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Carl D. Walkey
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Ryan Swanson
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Michael Gale Jr
3Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, WA 98195, USA
Luis M. Blancas-Mejia
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Hui-Ling Yen
2School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China
Daniel-Adriano Silva
1Neoleukin Therapeutics Inc., Seattle, WA 98102, USA
Posted August 03, 2020.
De novo design of ACE2 protein decoys to neutralize SARS-CoV-2
Thomas W. Linsky, Renan Vergara, Nuria Codina, Jorgen W. Nelson, Matthew J. Walker, Wen Su, Tien-Ying Hsiang, Katharina Esser-Nobis, Kevin Yu, Yixuan J. Hou, Tanu Priya, Masaya Mitsumoto, Avery Pong, Uland Y. Lau, Marsha L. Mason, Jerry Chen, Alex Chen, Tania Berrocal, Hong Peng, Nicole S. Clairmont, Javier Castellanos, Yu-Ru Lin, Anna Josephson-Day, Ralph Baric, Carl D. Walkey, Ryan Swanson, Michael Gale Jr, Luis M. Blancas-Mejia, Hui-Ling Yen, Daniel-Adriano Silva
bioRxiv 2020.08.03.231340; doi: https://doi.org/10.1101/2020.08.03.231340
De novo design of ACE2 protein decoys to neutralize SARS-CoV-2
Thomas W. Linsky, Renan Vergara, Nuria Codina, Jorgen W. Nelson, Matthew J. Walker, Wen Su, Tien-Ying Hsiang, Katharina Esser-Nobis, Kevin Yu, Yixuan J. Hou, Tanu Priya, Masaya Mitsumoto, Avery Pong, Uland Y. Lau, Marsha L. Mason, Jerry Chen, Alex Chen, Tania Berrocal, Hong Peng, Nicole S. Clairmont, Javier Castellanos, Yu-Ru Lin, Anna Josephson-Day, Ralph Baric, Carl D. Walkey, Ryan Swanson, Michael Gale Jr, Luis M. Blancas-Mejia, Hui-Ling Yen, Daniel-Adriano Silva
bioRxiv 2020.08.03.231340; doi: https://doi.org/10.1101/2020.08.03.231340
Subject Area
Subject Areas
- Biochemistry (11730)
- Bioengineering (8743)
- Bioinformatics (29179)
- Biophysics (14964)
- Cancer Biology (12080)
- Cell Biology (17399)
- Clinical Trials (138)
- Developmental Biology (9417)
- Ecology (14174)
- Epidemiology (2067)
- Evolutionary Biology (18294)
- Genetics (12233)
- Genomics (16791)
- Immunology (11858)
- Microbiology (28051)
- Molecular Biology (11575)
- Neuroscience (60919)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4955)
- Plant Biology (10422)
- Synthetic Biology (2881)
- Systems Biology (7338)
- Zoology (1650)